These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6271842)

  • 1. Cannabinoids in glaucoma: a primary screening procedure.
    Elsohly MA; Harland E; Murphy JC; Wirth P; Waller CW
    J Clin Pharmacol; 1981; 21(S1):472S-478S. PubMed ID: 6271842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit.
    ElSohly MA; Harland EC; Benigni DA; Waller CW
    Curr Eye Res; 1984 Jun; 3(6):841-50. PubMed ID: 6329602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol.
    Chesher GB; Jackson DM
    Pharmacol Biochem Behav; 1985 Jul; 23(1):13-5. PubMed ID: 2994117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure following systemic administration of cannabinoids.
    Green K; Symonds CM; Oliver NW; Elijah RD
    Curr Eye Res; 1982-1983; 2(4):247-53. PubMed ID: 6295702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.
    Zuardi AW; Shirakawa I; Finkelfarb E; Karniol IG
    Psychopharmacology (Berl); 1982; 76(3):245-50. PubMed ID: 6285406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids.
    Liu JH; Dacus AC
    Arch Ophthalmol; 1987 Feb; 105(2):245-8. PubMed ID: 3813958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. I. In vivo investigation of the primary and secondary immune response.
    Baczynsky WO; Zimmerman AM
    Pharmacology; 1983; 26(1):1-11. PubMed ID: 6298841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behaviour in rats maintained by low differential reinforcement rate: effects of delta 1-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combination.
    Hiltunen AJ; Järbe TU; Kamkar MR; Archer T
    Neuropharmacology; 1989 Feb; 28(2):183-9. PubMed ID: 2541367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol attenuates delta 9-tetrahydrocannabinol-like discriminative stimulus effects of cannabinol.
    Hiltunen AJ; Järbe TU
    Eur J Pharmacol; 1986 Jun; 125(2):301-4. PubMed ID: 3017729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid.
    Beilin M; Neumann R; Belkin M; Green K; Bar-Ilan A
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):217-30. PubMed ID: 10872919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain.
    Alozie SO; Martin BR; Harris LS; Dewey WL
    Pharmacol Biochem Behav; 1980 Feb; 12(2):217-21. PubMed ID: 6246544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft cannabinoid analogues as potential anti-glaucoma agents.
    Buchwald A; Browne CE; Wu WM; Ji F; Bodor N
    Pharmazie; 2000 Mar; 55(3):196-201. PubMed ID: 10756540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.
    Tomida I; Azuara-Blanco A; House H; Flint M; Pertwee RG; Robson PJ
    J Glaucoma; 2006 Oct; 15(5):349-53. PubMed ID: 16988594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes.
    Baczynsky WO; Zimmerman AM
    Pharmacology; 1983; 26(1):12-9. PubMed ID: 6298842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Should ophtalmologists recommend medical cannabis to patients with glaucoma?].
    Mouhammad ZA; Kolko M
    Ugeskr Laeger; 2018 Jul; 180(29):. PubMed ID: 30020072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soft cannabinoid analogues as potential anti-glaucoma agents.
    Buchwald A; Derendorf H; Ji F; Nagaraja NY; Wu WM; Bodor N
    Pharmazie; 2002 Feb; 57(2):108-14. PubMed ID: 11878185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic use of cannabinoids: Forensic aspects.
    Indorato F; Liberto A; Ledda C; Romano G; Barbera N
    Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between delta 9-tetrahydrocannabinol and cannabidiol as evaluated by drug discrimination procedures in rats and pigeons.
    Hiltunen AJ; Järbe TU
    Neuropharmacology; 1986 Feb; 25(2):133-42. PubMed ID: 3010159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.
    Lötsch J; Weyer-Menkhoff I; Tegeder I
    Eur J Pain; 2018 Mar; 22(3):471-484. PubMed ID: 29160600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
    Adelli GR; Bhagav P; Taskar P; Hingorani T; Pettaway S; Gul W; ElSohly MA; Repka MA; Majumdar S
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2167-2179. PubMed ID: 28399267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.